Salicylaldehyde isonicotinoyl hydrazone (SIH) is an intracellular iron chelator with well documented potential to protect against oxidative injury both in vitro and in vivo. However, it suffers from short biological half-life caused by fast hydrolysis of the hydrazone bond. Recently, a concept of boronate prochelators has been introduced as a strategy that might overcome these limitations. This study presents two complementary analytical methods for detecting the prochelator-boronyl salicylaldehyde isonicotinoyl hydrazone-BSIH along with its active metal-binding chelator SIH in different solution matrices and concentration ranges. An LC-UV method for determination of BSIH and SIH in buffer and cell culture medium was validated over concentrations of 7-115 and 4-115 μM, respectively, and applied to BSIH activation experiments in vitro. An LC-MS assay was validated for quantification of BSIH and SIH in plasma over the concentration range of 0.06-23 and 0.24-23 μM, respectively, and applied to stability studies in plasma in vitro as well as analysis of plasma taken after i.v. administration of BSIH to rats. A Zorbax-RP bonus column and mobile phases containing either phosphate buffer with EDTA or ammonium formate and methanol/acetonitrile mixture provided suitable conditions for the LC-UV and LC-MS analysis, respectively. Samples were diluted or precipitated with methanol prior to analysis. These separative analytical techniques establish the first validated protocols to investigate BSIH activation by hydrogen peroxide in multiple matrices, directly compare the stabilities of the prochelator and its chelator in plasma, and provide the first basic pharmacokinetic data of this prochelator. Experiments reveal that BSIH is stable in all media tested and is partially converted to SIH by H2O2. The observed integrity of BSIH in plasma samples from the in vivo study suggests that the concept of prochelation might be a promising strategy for further development of aroylhydrazone cytoprotective agents.

Duke University Department of Chemistry Durham NC 22708 USA

Faculty of Pharmacy in Hradec Králové Charles University Prague Heyrovského 1203 500 05 Hradec Králové Czech Republic

Zobrazit více v PubMed

Sterba M, Popelova O, Vavrova A, Jirkovsky E, Kovarikova P, Gersl V, Simunek T. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid. Redox. Signal. 2013;18:899–929. PubMed PMC

Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003;108:1912–1916. PubMed

Reif DW. Ferritin as a source of iron for oxidative damage. Free Radic. Biol. Med. 1992;12:417–427. PubMed

Simunek T, Boer C, Bouwman RA, Vlasblom R, Versteilen AM, Sterba M, Gersl V, Hrdina R, Ponka P, de Lange JJ, Paulus WJ, Musters RJ. SIH--a novel lipophilic iron chelator--protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. J. Mol. Cell. Cardiol. 2005;39:345–354. PubMed

Horackova M, Ponka P, Byczko Z. The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H(2)O(2) injury in adult cardiomyocytes. Cardiovasc. Res. 2000;47:529–536. PubMed

Kurz T, Gustafsson B, Brunk UT. Intralysosomal iron chelation protects against oxidative stress-induced cellular damage. FEBS J. 2006;273:3106–3117. PubMed

Bendova P, Mackova E, Haskova P, Vavrova A, Jirkovsky E, Sterba M, Popelova O, Kalinowski DS, Kovarikova P, Vavrova K, Richardson DR, Simunek T. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem. Res. Toxicol. 2010;23:1105–1114. PubMed

Haskova P, Kovarikova P, Koubkova L, Vavrova A, Mackova E, Simunek T. Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity. Free Radic. Biol. Med. 2011;50:537–549. PubMed

Simunek T, Sterba M, Popelova O, Kaiserova H, Adamcova M, Hroch M, Haskova P, Ponka P, Gersl V. Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone. Br. J. Pharmacol. 2008;155:138–148. PubMed PMC

Sterba M, Popelova O, Simunek T, Mazurova Y, Potacova A, Adamcova M, Guncova I, Kaiserova H, Palicka V, Ponka P, Gersl V. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH) Toxicology. 2007;235:150–166. PubMed

Klimtova I, Simunek T, Mazurova Y, Kaplanova J, Sterba M, Hrdina R, Gersl V, Adamcova M, Ponka P. A study of potential toxic effects after repeated 10-week administration of a new iron chelator--salicylaldehyde isonicotinoyl hydrazone (SIH) to rabbits. Acta medica. 2003;46:163–170. PubMed

Kovarikova P, Klimes J, Sterba M, Popelova O, Mokry M, Gersl V, Ponka P. Development of high-performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to an in vivo study. J. Sep. Sci. 2005;28:1300–1306. PubMed

Kovarikova P, Mrkvickova Z, Klimes J. Investigation of the stability of aromatic hydrazones in plasma and related biological material. J. Pharm. Biomed. Anal. 2008;47:360–370. PubMed

Charkoudian LK, Pham DM, Kwon AM, Vangeloff AD, Franz KJ. Modifications of boronic ester pro-chelators triggered by hydrogen peroxide tune reactivity to inhibit metal-promoted oxidative stress. Dalton Trans. 2007:5031–5042. PubMed

Charkoudian LK, Pham DM, Franz KJ. A pro-chelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation. J. Am. Chem. Soc. 2006;128:12424–12425. PubMed

Zielonka J, Sikora A, Hardy M, Joseph J, Dranka BP, Kalyanaraman B. Boronate probes as diagnostic tools for real time monitoring of peroxynitrite and hydroperoxides. Chem. Res. Toxicol. 2012;25:1793–1799. PubMed PMC

Charkoudian LK, Dentchev T, Lukinova N, Wolkow N, Dunaief JL, Franz KJ. Iron prochelator BSIH protects retinal pigment epithelial cells against cell death induced by hydrogen peroxide. J. Inorg. Biochem. 2008;102:2130–2135. PubMed PMC

Kovarikova P, Mokry M, Klime J, Vavrova K. Chromatographic methods for the separation of biocompatible iron chelators from their synthetic precursors and iron chelates. J. Sep. Sci. 2004;27:1503–1510. PubMed

Becker EM, Lovejoy DB, Greer JM, Watts R, Richardson DR. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. Br. J. Pharmacol. 2003;138:819–830. PubMed PMC

FDA, Center for Drug Evaluation and Research (CDER) Bioanalytical method validation guidance for industry. 2001 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.

Kielar F, Helsel ME, Wang Q, Franz KJ. Prochelator BHAPI protects cells against paraquat-induced damage by ROS-triggered iron chelation. Metallomics. 2012;4:899–909. PubMed PMC

Buss PPJL. Hydrolysis of pyridoxal isonicotinoyl hydrazone and its analogs. Biochim. Biophys. Acta-Gen. Subj. 2003;1619:177–186. PubMed

Jansova H, Machacek M, Wang Q, Haskova P, Vavrova A, Potuckova E, Kielar F, Franz KJ, Simunek T. Comparison of various iron chelators and prochelators as protecting agents against cardiomyocyte oxidative injury. Free Radic. Biol. Med. 2014;74:210–221. PubMed PMC

Menezes JC, Cavaleiro JA, Kamat SP, Barros CM, Domingues MR. Electrospray tandem mass spectrometry analysis of methylenedioxy chalcones, flavanones and flavones. Rapid Commun. Mass. Spectrom. 2013;27:1303–1310. PubMed

Kuhn F, Oehme M, Romero F, Abou-Mansour E, Tabacchi R. Differentiation of isomeric flavone/isoflavone aglycones by MS2 ion trap mass spectrometry and a double neutral loss of CO. Rapid Commun. Mass. Spectrom. 2003;17:1941–1949. PubMed

Kovarikova P, Klimes J, Sterba M, Popelova O, Gersl V, Ponka P. HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study. J. Chromatogr. B. 2006;838:107–112. PubMed

Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine

Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury

Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products